Crystal Rock Capital Management Increases Holdings in Eli Lilly and Company $LLY

Crystal Rock Capital Management increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 41.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,175 shares of the company’s stock after buying an additional 935 shares during the quarter. Eli Lilly and Company comprises 1.4% of Crystal Rock Capital Management’s holdings, making the stock its 23rd largest position. Crystal Rock Capital Management’s holdings in Eli Lilly and Company were worth $2,475,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter worth approximately $27,000. Blume Capital Management Inc. lifted its position in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the second quarter worth $35,000. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth $40,000. Finally, TD Capital Management LLC increased its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO David A. Ricks bought 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on LLY shares. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, UBS Group cut their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Trading Up 2.2%

Shares of NYSE LLY opened at $862.96 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a fifty day simple moving average of $780.74 and a 200-day simple moving average of $771.71. The stock has a market capitalization of $816.76 billion, a PE ratio of 56.40, a PEG ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the firm posted $1.18 earnings per share. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.